Literature DB >> 23583893

Reflections on the early development of poxvirus vectors.

Bernard Moss1.   

Abstract

Poxvirus expression vectors were described in 1982 and quickly became widely used for vaccine development as well as research in numerous fields. Advantages of the vectors include simple construction, ability to accommodate large amounts of foreign DNA and high expression levels. Numerous poxvirus-based veterinary vaccines are currently in use and many others are in human clinical trials. The early reports of poxvirus vectors paved the way for and stimulated the development of other viral vectors and recombinant DNA vaccines. Published by Elsevier Ltd.

Entities:  

Keywords:  DNA cloning; Recombinant DNA; Recombinant vaccines; Vaccine vectors; Vaccinia virus

Mesh：

Substances：

Year:  2013        PMID： 23583893      PMCID： PMC3755097          DOI： 10.1016/j.vaccine.2013.03.042

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  61 in total

1.  The complete DNA sequence of vaccinia virus.

Authors:  S J Goebel; G P Johnson; M E Perkus; S W Davis; J P Winslow; E Paoletti
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Efficacy studies on a canarypox-rabies recombinant virus.

Authors:  J Taylor; C Trimarchi; R Weinberg; B Languet; F Guillemin; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

3.  New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins.

Authors:  A J Davison; B Moss
Journal:  Nucleic Acids Res       Date:  1990-07-25       Impact factor: 16.971

4.  Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.

Authors:  T R Fuerst; P L Earl; B Moss
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

5.  Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.

Authors:  C Flexner; A Hügin; B Moss
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

6.  NYVAC: a highly attenuated strain of vaccinia virus.

Authors:  J Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

7.  Construction of recombinant fowlpox viruses as vectors for poultry vaccines.

Authors:  D B Boyle; B E Coupar
Journal:  Virus Res       Date:  1988-06       Impact factor: 3.303

8.  Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.

Authors:  P L Earl; A W Hügin; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

9.  Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein.

Authors:  J J Esposito; J C Knight; J H Shaddock; F J Novembre; G M Baer
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

10.  Recombinant fowlpox virus inducing protective immunity in non-avian species.

Authors:  J Taylor; R Weinberg; B Languet; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641
View more
  24 in total

1.  Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs during Vaccinia Virus-Induced Host Shutoff.

Authors:  Aimei Dai; Shuai Cao; Pragyesh Dhungel; Yizhao Luan; Yizhi Liu; Zhi Xie; Zhilong Yang
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

2.  Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.

Authors:  Xiaoli Wang; Sytse J Piersma; Jabari I Elliott; John M Errico; Maria D Gainey; Liping Yang; Christopher A Nelson; Wayne M Yokoyama; Daved H Fremont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-01       Impact factor: 11.205

3.  Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity.

Authors:  Ariana G Bravo Cruz; Aiguo Han; Edward J Roy; Arielle B Guzmán; Rita J Miller; Elizabeth A Driskell; William D O'Brien; Joanna L Shisler
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

4.  The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice.

Authors:  D S O Daian E Silva; T M G Pinho; M A Rachid; D F Barbosa-Stancioli; F G Da Fonseca
Journal:  Braz J Microbiol       Date:  2019-03-15       Impact factor: 2.476

5.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

6.  Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.

Authors:  Ming Yuan; Wensheng Zhang; Jun Wang; Chadwan Al Yaghchi; Jahangir Ahmed; Louisa Chard; Nick R Lemoine; Yaohe Wang
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

Review 7.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

8.  Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.

Authors:  Bahar Ramezanpour; Esther S Pronker; Joost H C M Kreijtz; Albert D M E Osterhaus; E Claassen
Journal:  Vaccine       Date:  2015-06-03       Impact factor: 3.641

Review 9.  Current progress in gene delivery technology based on chemical methods and nano-carriers.

Authors:  Lian Jin; Xin Zeng; Ming Liu; Yan Deng; Nongyue He
Journal:  Theranostics       Date:  2014-01-15       Impact factor: 11.556

Review 10.  Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

Authors:  Chadwan Al Yaghchi; Zhongxian Zhang; Ghassan Alusi; Nicholas R Lemoine; Yaohe Wang
Journal:  Immunotherapy       Date:  2015-11-23       Impact factor: 4.196
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.